Showing results (521-530 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|February 29, 2024
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi ArabiaHussain A Al-Omar, Hind S Almodaimegh, Abubker Omaer, et al.Journal of Medical Economics|February 20, 2024
Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational studyYong Wang, Chunxiao Liu, Chuan Liu, et al.Journal of Medical Economics|February 19, 2024
A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic strokeScott E Kasner, Lars Sondergaard, Mitesh Nakum, et al.Journal of Medical Economics|November 7, 2023
Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi ArabiaMohammed Alluhidan, Hana Alabdulkarim, Ali Alrumaih, et al.Journal of Medical Economics|November 1, 2023
Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United StatesNovember McGarvey, Matthew Gitlin, Ela Fadli, et al.Journal of Medical Economics|October 30, 2023
Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort studyYan Wang, Weihua Gao, Xu Han, et al.Journal of Medical Economics|November 14, 2023
Socioeconomic effects of establishing a new stroke center in Central SwitzerlandA von Hessling, M Stuecheli, V Seguel Ravest, et al.Journal of Medical Economics|November 2, 2023
The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspectiveEkaterina Ponomareva, Luke Schmerold, Srinivas Sss, et al.Journal of Medical Economics|October 19, 2023
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of ChinaKehong Yang, Susan Hua, Wenting Wei, et al.Journal of Medical Economics|October 6, 2023
A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix in patients diagnosed with non-muscle-invasive bladder cancer in FranceJonathan BelseyPageof 241